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Obesity is an important risk factor for osteoarthritis (OA) in weight-bearing joints, but also in hand joints, pointing to an obesity-
related metabolic factor that influences on the pathogenesis of OA. Leptin is an adipokine regulating energy balance, and it has
recently been related also to arthritis and inflammation as a proinflammatory factor. In the present paper, the eﬀects of leptin
on human OA cartilage were studied. Leptin alone or in combination with IL-1 enhanced the expression of iNOS and COX-
2, and production of NO, PGE2, IL-6, and IL-8. The results suggest that the eﬀects of leptin are mediated through activation
of transcription factor nuclear factor κB (NF-κB) and mitogen-activated protein kinase (MAPK) pathway c-Jun NH2-terminal
kinase (JNK). Interestingly, inhibition of leptin-induced NO production with a selective iNOS inhibitor 1400 W inhibited also the
production of IL-6, IL-8, and PGE2, and this was reversed by exogenously added NO-donor SNAP, suggesting that the eﬀects of
leptin on IL-6, IL-8, and PGE2 production are dependent on NO. These findings support the idea of leptin as a factor enhancing
the production of proinflammatory factors in OA cartilage and as an agent contributing to the obesity-associated increased risk
for osteoarthritis.
Copyright © 2009 Katriina Vuolteenaho et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Introduction
Leptin is a hormone that was initially found to be synthesized
by white adipocytes and has a strong correlation with the
amount of adipose tissue and with body mass index (BMI).
Leptin was first discovered in 1994 and found to act as
a signal for the central nervous system to inhibit food
intake and to stimulate energy expenditure [1]. More recent
findings on the ubiquitous expression of leptin receptors in
almost all tissues and on its cellular eﬀects have revealed
that leptin is also involved in the regulation of a variety
of biological functions related to immune responses and
inflammatory diseases, and to cardiovascular and respiratory
pathophysiology [2–5].
Obesity is an important risk factor for osteoarthritis
(OA) [6]. Increased joint loading and altered mechanic
loading axis has been proposed to explain the increased risk
of OA in weight-bearing joints, including hip and knee joints.
Surprisingly, there is also a positive association between
obesity and OA in the hand, pointing to an obesity related
metabolic factor that acts as a risk factor for OA. Recently,
it has been shown that synovial fluid (SF) from OA patients
contains leptin concentrations that are similar or higher than
those measured in serum [7–9]. Furthermore, low soluble
leptin receptor (sOb-R) level in SF potentiates the biological
activity of leptin in the joint as compared to that in serum
[8]. Articular cartilage has been reported to produce leptin
[8, 10] and express functional leptin receptor Ob-R [11], and
the expression of these two is further increased in advanced
OA correlating with BMI of the patients [9].
In vitro, leptin has been shown to potentiate interleukin-
1 (IL-1) and interferon γ (IFNγ)-induced production of
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nitric oxide (NO) in chondrocytes, which is a proinflamma-
tory and destructive mediator in cartilage [12, 13]. Leptin
has been shown to decrease chondrocyte proliferation and
to increase production of proinflammatory cytokine IL-1β
and destructive matrix metalloproteinases 9 and 13 (MMP-9
and 13) in human chondrocytes [9, 14]. On the other hand,
leptin has also been reported to increase proliferation and
to enhance proteoglycan and collagen synthesis in human
chondrocytes [11]. In vivo, leptin injection into rat knee was
reported to increase synthesis of insulin-like growth factor
1 (IGF-I) and transforming growth factor β (TGFβ) both
contributing to increased proteoglycan synthesis [7]. These
eﬀects are linked to increased cartilage matrix production,
and also to osteophyte formation.
NO is related to the pathogenesis of OA as a destructive
mediator [15]. Inducible nitric oxide synthase (iNOS) is
expressed in OA cartilage, and there are markers of enhanced
NO production in OA joints [15, 16]. Prostaglandins (PGs),
especially PGE2, mediate inflammation, tissue destruction,
and pain in OA and in OA joints they are formed
by cyclooxygenase (COX) enzymes (particularly COX-2)
and prostaglandin synthases [17]. Interleukin-6 (IL-6) and
interleukin-8 (IL-8) are produced by OA cartilage and have
a proinflammatory and modulatory role in the pathogenesis
of OA [10, 18].
The presence of bioactive leptin in OA joint and the
eﬀects of leptin on cartilage metabolism point to a patho-
physiological role for leptin in OA. The aim of the present
study was to investigate the eﬀects of leptin on mediators
of cartilage metabolism by measuring its eﬀects on the
production of NO, PGE2, IL-6, and IL-8 in OA cartilage and
by evaluating the signaling mechanisms involved in these
eﬀects by pharmacological means.
2. Materials and Methods
2.1. Patients and Cartilage Cultures. Cartilage tissue was
obtained from the leftover pieces of total knee replacement
surgery. The study was approved by the Ethics Committee
of Tampere University Hospital, and the patients gave their
written approval. The donor patients, age ranging from 53 to
87 years and body mass index ranging from 20 to 32, were all
diagnosed to have osteoarthritis.
Cartilage samples were washed with phosphate buﬀered
saline (PBS) and processed for the experiments within
two hours after the operation. Full thickness pieces of
articular cartilage from femoral condyles, tibial plateaus,
and patellar surfaces showing macroscopical features of
early OA were removed aseptically from subchondral bone
with a scalpel and cut into small pieces (about 2 × 2 ×
2 mm). Cartilage cubes randomly selected from 3 diﬀerent
areas of the joint were incubated in one well of a 6-
well plate in 3 mL of tissue culture medium (Dulbecco’s
modified Eagle’s medium (DMEM) with glutamax-I con-
taining 10% heat-inactivated fetal bovine serum, penicillin
(100 units/mL), streptomysin (100 μg/mL), and ampho-
tericin B (250 ng/mL); all obtained from Invitrogen, Carls-
bad, Calif, USA)) at 37◦C in humidified 5% carbon dioxide
atmosphere.
In the first two series of experiments, OA carti-
lage explants from 8 patients were incubated with leptin
(0.1 μg/mL or 10 μg/mL) alone or in combination with IL-
1β (10 pg/mL) for 48 hours. Concentrations of NO, PGE2,
IL-6, and IL-8 were determined in the culture medium. In
the third series of experiments OA explants from 3 patients
were incubated with leptin (0.1 μg/mL or 10 μg/mL) alone
or in combination with IL-1β (10 pg/mL) for 48 hours.
Cartilage samples were used to determine expression of
iNOS and COX-2 protein. In the fourth series of experi-
ments, signaling mechanisms involved in the leptin-induced
NO, PGE2, IL-6, and IL-8 production were studied using
pharmacological inhibitors. OA explants from 7 patients
were incubated for 48 hours with leptin (10 μg/mL) and
following signaling pathway inhibitors: SP600125 10 μM
(JNK inhibitor), SB220025 0.5 μM (p38 inhibitor), PD98059
10 μM (Erk1/2 inhibitor), AG490 10 μM (JAK2 inhibitor),
WHI-P154 10 μM (JAK3 inhibitor), Ro 31-8220 1 μM (PKC
inhibitor), MG132 10 μM (NF-κB inhibitor), and PDTC
10 μM (NF-κB inhibitor). Concentrations of NO, PGE2,
IL-6, and IL-8 were determined in the culture medium.
In the fifth series of experiments, the eﬀect of NO on
leptin-induced (10 μg/mL) IL-6, IL-8, and PGE2 production
was studied by inhibiting leptin-induced endogenous NO
production with a selective iNOS inhibitor 1400 W (1 mM)
during a 48 hour incubation of OA explants from 8
patients. The eﬀect of NO was further investigated by
studying if exogenous NO could reverse the eﬀects of
iNOS inhibitor 1400 W in leptin-treated cartilage. This was
made by adding NO-donor SNAP (100 μM) together with
1400 W and leptin in the cartilage cultures. Concentrations
of NO, PGE2, IL-6, and IL-8 were determined in the culture
medium.
After the experiment the cartilage explants were weighed,
and the results were expressed per mg of cartilage. Aliquots
of the culture media were kept at −20◦C until assayed, and
cartilage samples for Western blotting were first snap frozen
in liquid nitrogen and analysed as described below.
2.2. NO Production. Concentrations of nitrite, a stable
product of NO in aqueous solutions, were measured using
the Griess reaction [19]. The results were expressed as pmol
of nitrite/mg of cartilage.
2.3. Prostaglandin E2 Assays. The amount of PGE2 released
into the incubation medium was determined by radioim-
munoassay, using reagents from the Institute of Isotopes
(Budapest, Hungary). The results were expressed as pg of
PGE2/mg of cartilage.
2.4. IL-6 and IL-8 Assays. The concentrations of IL-6 (San-
quin, PeliPair, Amsterdam, The Netherlands) and IL-8 (R&D
Systems, Minneapolis, MN, USA) in the culture medium
were determined by ELISA. The results were expressed as pg
of IL-6/mg of cartilage, or pg of IL-8/mg of cartilage.
2.5. Western Blot Analysis. After incubations, the cartilage
specimen were snap frozen in liquid nitrogen, milled
and lysed in extraction buﬀer (10 mM Tris-HCl, 5 mM
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EDTA, 50 mM NaCl, 1% Triton-X-100, 0.5 mM phenyl-
methylsulfonylfluoride (PMSF), 1 mM sodiumorthovana-
date, 20 μg/mL leupeptin, 50 μg/mL aprotin, 5 mM sodium
fluoride, 2 mM sodium pyrophosphate, 10 μM n-octyl-beta-
D-glucopyranoside). Following incubation on ice for 15
minutes, samples were centrifuged and supernatants were
mixed with sample buﬀer 1 : 4 (62.5 mM Tris-HCl, pH
6.8, 10% glycerol, 2% SDS, 0.025% bromophenol blue,
and 5% β-mercaptoethanol) and stored at −20◦C until
analyzed. Coomassie blue method was used to measure the
protein content of the samples [20]. After boiling, protein
samples (20 μg) were separated with 8% SDS-polyacrylamide
electrophoresis gels and transferred to Hybond enhanced
chemiluminescence nitrocellulose membrane (Amersham
Biosciences UK Limited, Buckinghamshire, UK). Proteins
were identified by Western blotting using rabbit polyclonal
antibody for human iNOS and goat polyclonal antibody for
human COX-2 (both obtained from Santa Cruz Biotechnol-
ogy, Santa Cruz, Calif, USA). Actin was analysed as a loading
control by using rabbit polyclonal antibody (Santa Cruz
Biotechnology, Santa Cruz, Calif, USA). Bound antibody
was detected using SuperSignal West Pico chemiluminescent
substrate (Pierce, Rockford, IL, USA) and FluorChem 8800
imaging system (Alpha Innotech, San Leandro, Calif, USA).
Quantitation of the chemiluminescent signal was carried out
with FluorChem software v.3.1.
2.6. Statistical Analysis. Results are expressed as mean ±
standard error of the mean (SEM). Statistical significance of
the results was calculated by using paired t-test.
2.7. Materials. Recombinant Human Leptin and Recombi-
nant Human IL-1 beta were purchased from R&D Systems;
manufacturer ensures low endotoxin level of the products
(<1.0 EU per 1 μg of the recombinant protein), and that
amount in relation to the leptin concentrations used in the
present study was tested to have no eﬀect in our tissue
culture conditions. Other reagents were obtained as follows:
SP600125, SB220025, AG 490 and WHI-P154 were from
Calbiochem (Merck, Darmstadt, Germany); PD 98059 was
from Promega (Madison, WI, USA); Ro 31-8220 was from
Alexis Corporation (Lausen, Switzerland); MG 132 was from
Tocris Bioscience (Ellisville, MO, USA); PDTC was from
Sigma Chemical Co (St Louis, MO, USA); SNAP was from
Cayman Chemical (Ann Arbor, MI, USA). 1400 W was
kindly given by Dr Richard G Knowles, Glaxo SmithKline
Research & Development, Stevenage, UK.
3. Results
3.1. The Eﬀects of Leptin on NO, PGE2, IL-6, and IL-8
Production in Human OA Cartilage. Leptin (0.1 μg/mL and
10 μg/mL) enhanced NO production in OA cartilage in a
dose-dependent manner (Figure 1(a)). Western blot analysis
with human iNOS antibody showed that leptin (10 μg/mL)
induced also iNOS expression in cultured cartilage tissue
(Figure 1(b)). In addition, leptin (10 μg/mL) increased PGE2
production and COX-2 expression, and IL-6 and IL-8 pro-
duction in human OA cartilage during 48 hours incubation
(Figures 1(c), 1(d), 1(e), and 1(f)).
A low concentration of proinflammatory cytokine IL-1β
(10 pg/mL) had a slight stimulatory eﬀect on NO, PGE2, IL-
6, and IL-8 production and iNOS and COX-2 expression
(Figure 2). Leptin (10 μg/mL) enhanced NO, PGE2, IL-6, and
IL-8 production, and iNOS and COX-2 expression in OA
cartilage also in the presence of IL-1β (Figure 2).
3.2. Signaling Mechanisms Involved in the Leptin-Induced
NO, PGE2, IL-6, and IL-8 Production. The involvement of
signaling pathways (JNK, p38, and Erk1/2 MAP-kinases,
JAK2 and JAK3, PKC, and transcription factor NF-κB) in
leptin-stimulated NO, PGE2, IL-6, and IL-8 production
in OA cartilage was studied by pharmacological means.
Inhibitors of transcription factor NF-κB, MG 132 (10 μM)
and PDTC (100 μM), and JNK inhibitor SP600125 (10 μM)
significantly inhibited leptin-induced NO, PGE2, IL-6, and
IL-8 production (Figure 3). In addition to the eﬀect of JNK
inhibitor, inhibitors of other MAP-kinases, that is, SB220025
(p38 inhibitor; 0.5 μM) and PD 98059 (Erk1/2 inhibitor;
10 μM) inhibited leptin-induced PGE2 production, but had
no eﬀect on NO, IL-6, or IL-8 production. JAK2 inhibitor
AG 490 (10 μM) had no eﬀect on leptin-induced NO, PGE2,
IL-6, or IL-8 production, whereas JAK3 inhibitor WHI-
P154 (10 μM) inhibited leptin-induced NO synthesis, but not
PGE2, IL-6, or IL-8 production. Leptin-induced NO, IL-6,
and IL-8 production was inhibitable with protein kinase C
inhibitor Ro 31-8220 (1 μM), while it had no eﬀect on PGE2
production.
3.3. The Eﬀect of NO on Leptin-Induced IL-6, IL-8, and PGE2
Production. A selective iNOS inhibitor 1400 W (1 mM)
inhibited leptin-induced NO production almost completely
indicating that it was synthesized through iNOS pathway
(Figure 4(a)). Interestingly, inhibition of NO production
with 1400 W reduced also the production of IL-6, IL-8, and
PGE2 (Figures 4(b)–4(d)). The eﬀect of 1400 W was reversed
when NO-donor SNAP (100 μM) was added into the culture.
Those results suggest that the increasing eﬀect of leptin on
IL-6, IL-8, and PGE2 production in human OA cartilage is
dependent on NO.
4. Discussion
Osteoarthritis is a chronic disease characterised by gradual
loss of the articular cartilage. The course of the destructive
process is determined by the balance between anabolic and
catabolic mediators and their regulators in the joint, and
the local distribution of these mediators in the cartilage
[18]. Leptin is an obesity related mediator, which has been
suggested to take part in the regulation of anabolic and
catabolic processes within the osteoarthritic joint and to play
a role in the pathogenesis of OA [21]. In the present study, we
found that leptin induced the production of NO, PGE2, IL-6,
and IL-8 in human osteoarthritic cartilage and that leptin-
induced PGE2, IL-6, and IL-8 production was dependent
on NO. These findings support the role of leptin in the
pathogenesis of OA.
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Figure 1: The eﬀect of leptin on NO production (a), iNOS protein expression (b), PGE2 production (c), COX-2 protein expression (d), IL-6
production (e), and IL-8 production (f) in human OA cartilage. Cartilage explants were incubated with leptin (0.1 μg/mL or 10 μg/mL) for
48 hours. NO production (a) was measured as nitrite accumulation in the culture medium by Griess reaction. Expression of iNOS protein (b)
and COX-2 protein (d) were measured by Western blot. PGE2 production (c) in the culture medium was measured by RIA. Concentrations
of IL-6 (e), and IL-8 (f) in the culture medium were measured by ELISA. Results are expressed as pmol/mg cartilage (a), as percentages in
comparison with control sample ((b) and (d)) or pg/mg cartilage ((c), (e), and (f)). Values are mean ± SEM. Samples were collected from 6
patients (n = 6) in (a) and (c), from 3 patients (n = 3) in (b) and (d), and from 7 patients (n = 7) in (e) and (f). #: P < .2, ∗: P < .05, and
∗∗: P < .01 as compared to control explants incubated in absence of exogenous leptin.
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Figure 2: The eﬀect of leptin on NO production (a), iNOS protein expression (b), PGE2 production (c), COX-2 protein expression (d),
IL-6 production (e), and IL-8 production (f) in human OA cartilage in the presence of IL-1β. Cartilage explants were incubated with IL-
1β (10 pg/mL) alone or in combination with leptin (0.1 μg/mL or 10 μg/mL) for 48 hours. NO production (a) was measured as nitrite
accumulation in the culture medium by Griess reaction. Expression of iNOS protein (b) and COX-2 protein (d) were measured by Western
blot. PGE2 production (c) in the culture medium was measured by RIA. Concentrations of IL-6 (e) and IL-8 (f) in the culture medium
were measured by ELISA. Results are expressed as pmol/mg cartilage (a), as percentages in comparison with control sample ((b) and (d)) or
pg/mg cartilage ((c), (e), and (f)). Values are mean ± SEM. Samples were collected from 6 patients (n = 6) in (a) and (c), from 3 patients
(n = 3) in (b) and (d), and from 7 patients (n = 7) in (e) and (f). #: P < .2, ∗: P < .05, and ∗∗: P < .01.
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Figure 3: The eﬀects of signaling pathway inhibitors on leptin induced NO (a), PGE2 (b), IL-6 (c), and IL-8 (d) production in human
OA cartilage. Cartilage explants were incubated for 48 hours with leptin (10 μg/mL) and the inhibitor indicated. NO production (a) was
measured as nitrite accumulation in the culture medium by Griess reaction. PGE2 production (b) in the culture medium was measured by
RIA. Levels of IL-6 (c), and IL-8 (d) in the culture medium were measured by ELISA. Leptin-induced NO/PGE2/IL-6/IL-8 production was
set as 100%, and the other values were related to that. The results are expressed as mean ± SEM. Samples were collected from 7 patients in
(a) and (b) (n = 7) and from 6 patients in (c) and (d) (n = 6). ∗: P < .05, ∗∗: P < .01, and ∗∗∗: P < .001 as compared to explants treated
with leptin alone.
NO mediates many of the destructive eﬀects of IL-1 in
inflamed joints [15, 16]. NO has been reported to increase
the production of matrix metalloproteinases (MMPs) and
to activate them [10, 22, 23], to inhibit proteoglycan [24–
26] and collagen [27] synthesis and to induce chondrocyte
cell death [28, 29]. NO is also involved in the progress
of inflammation by reducing the production of anti-
inflammatory/anabolic factors TGF-β [30], endogenous IL-1
receptor antagonist (IL-1ra), and IL-10 in chondrocytes [10,
31, 32], and by contributing to the resistance against anabolic
eﬀects of IGF-1 [33]. NO has also been shown to sustain
activation of NF-κB providing a prolonged transcription of
NF-κB dependent genes [34]. In support, Pelletier et al.
reported reduced destruction of the articular cartilage by
using iNOS-inhibitor L-NIL in instability-induced OA in
dogs [35]. In further studies with this model, L-NIL was
shown to reduce the levels of matrix metalloproteinase-1 and
-3 (MMP-1 and -3) [23], to inhibit chondrocyte apoptosis
[36] and to reduce the interleukin-1 converting enzyme
(ICE) levels [37]. Van den Berg et al. studied the development
of experimental osteoarthritis induced with intra-articular
collagenase injection in iNOS knock-out mice. In this model,
iNOS deficiency prevented the degree of cartilage destruction
and osteophyte formation [38]. NO has several catabolic and
antianabolic actions in cartilage and thus it is identified as a
possible target of treatment in osteoarthritis.
Leptin has been shown to induce or to potentiate
together with interferon γ (IFNγ), with tumor necrosis
factor α (TNFα) or with IFNγ and IL-1β, NO production
in murine J774A.1 macrophages, rat adipocytes, C6 glioma
cell-line, and rat vascular smooth muscle cells (VSMCs)
[39–42]. In human chondrocytes, leptin was reported to
enhance interleukin-1 (IL-1) and interferon γ (IFNγ)-
induced production of NO [12, 13]. In the present study,
we showed that leptin alone is suﬃcient to induce the iNOS
expression and NO production in human OA cartilage, and
an enhancing eﬀect was seen also in the presence of low
concentrations of IL-1β (Figures 1(a), 1(b), and 2(a), 2(b)).
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Figure 4: The eﬀects of a selective iNOS inhibitor 1400 W (1 mM) ((a)–(d)) with and without NO-donor SNAP ((b)–(d)) on leptin
(10 μg/mL) induced NO (a), IL-6 (b), IL-8 (c), and PGE2 (d) production in OA cartilage during 48 hours incubation. In the culture medium,
NO production (a) was measured as nitrite accumulation by Griess reaction, levels of IL-6 (b) and IL-8 (c) were measured by ELISA, and
PGE2 production (d) was measured by RIA. Leptin-induced NO/PGE2/IL-6/IL-8 production was set as 100%, and the other values were
related to that. The results are expressed as mean ± SEM. Samples were collected from 8 patients in (a) (n = 8), from 6 patients in (b)
(n = 6), from 8 patients in (c) (n = 8), and from 6 patients in (d) (n = 6). #: P < .2, ∗∗∗: P < .001.
Prostaglandins (especially PGE2) are produced in
high amounts in OA cartilage and are modulators of
inflammation, tissue destruction, and inflammatory pain.
Prostaglandins are formed from arachidonic acid by the
prostaglandin synthesizing cyclooxygenase (COX) enzymes
and prostaglandin synthases [17]. COX-2 is highly expressed
in OA cartilage and is induced by various cytokines that
are involved in destructive processes in OA cartilage, for
example, IL-1 and TNFα [43–45]. Current drug therapy
of OA is based on nonsteroidal anti-inflammatory drugs
(NSAIDs). NSAIDs inhibit COX enzymes and prostanoid
production, and they are used to relieve OA pain [46, 47].
To our knowledge, we show here for the first time that leptin
increases COX-2 expression and PGE2 production in human
OA cartilage in the absence and in the presence of IL-1
(Figures 1(c), 1(d) and 2(c), 2(d)). Previously, leptin has
been shown to induce PGE2 production in OE33 Barret’s
esophageal adenocarcinoma (EAC) cell-line and in murine
J774A.1 macrophages [39, 48].
Proinflammatory and regulatory cytokines IL-6 and IL-
8 are found in SF from OA patients [49]. OA cartilage
produces IL-6 and IL-8, and quantitative RT-PCR studies
have shown elevated IL-6 and IL-8 mRNA levels in OA
cartilage as compared to normal cartilage [10, 50]. Cytokines
IL-1β and TNFα which induce destructive eﬀects in cartilage
both induce IL-6 and IL-8 production in human articular
chondrocytes [51]. IL-6 and IL-8 may promote inflammation
and cartilage destruction induced by IL-1 or TNFα and have
a modulatory role in the pathogenesis of OA [18, 52–54].
In the present study, we show for the first time that leptin
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enhances IL-6 and IL-8 production in human OA cartilage
(Figures 1(e), 1(f) and 2(e), 2(f)). Leptin has previously
been shown to induce IL-6 production in human dendritic
cells, human monocytes, human endometrial stromal cells
(ESC), and in epithelial cells [55–57], and to stimulate IL-8
production in human endometrial stromal cells (ESCs) and
in epithelial cells [56].
Leptin signaling through leptin receptors (Ob-R) is
thought to be mediated through janus kinase/signal trans-
ducer and activator of transcription (JAK/STAT) pathway
and in addition to this, also mitogen-activated protein
kinases (MAPKs), protein kinase C (PKC), phosphatidyli-
nositol 3-kinase (PI3K), and nuclear factor κB (NF-κB)
pathways have been reported to mediate some eﬀects of
leptin, depending on the cell type [3, 58]. In chondrocytes,
Otero et al. showed by using pharmacological inhibitors that
induction of NO production with a combination of leptin
and IL-1 or IFNγ was dependent on JAK2, PI3K, Erk1/2, and
p38 [12, 13, 59], but these studies did not show signaling
pathways involved in the responses induced by leptin alone.
We studied the eﬀects of inhibitors of JAK (JAK2 and JAK3),
MAPK (Erk1/2, p38, JNK), PKC and NF-κB pathways on
leptin-induced NO, PGE2, IL-6, and IL-8 production in OA
cartilage. There seems to be some diﬀerences in the signaling
pathways important for production of the four diﬀerent
leptin-induced inflammatory molecules in OA cartilage.
Leptin-induced NO production was suppressed by inhibitors
of JNK, JAK3, PKC, and NF-κB, while leptin-induced PGE2
production was reduced by inhibitors of JNK, p38, and
Erk1/2 MAPkinases and transcription factor NF-κB. Leptin-
induced IL-6 and IL-8 production was reduced by inhibitors
of JNK, PKC, and NF-κB (Figure 3).
In the present study, inhibition of leptin-induced
endogenous NO production in OA cartilage with a selective
iNOS inhibitor 1400 W also suppressed the eﬀects of leptin
on PGE2, IL-6, and IL-8 production. The eﬀect was reversed
with exogenously added NO (NO-donor SNAP) (Figure 4).
Those results suggest that leptin induces PGE2, IL-6, and IL-
8 production in OA cartilage by an NO-dependent manner.
The mediator role of NO in leptin-induced metabolic
changes in human OA cartilage has not been reported
previously. It is, however, supported by the previous findings
on the involvement of NO in the eﬀects of leptin in some
other organ systems, that is, in the secretion of luteinizing
hormone-releasing hormone from the pituitary gland, in the
control of blood pressure, and in the gastroprotection upon
vagal activity [60–62].
In conclusion, OA cartilage was shown to respond to
leptin by producing increased amounts of NO, PGE2, IL-
6, IL-8, and all those eﬀects can be considered harmful
in cartilage metabolism. Those eﬀects of leptin seem to
be dependent on activation of transcription factor NF-κB
and the MAPK pathway c-Jun NH2-terminal kinase (JNK)
in human OA cartilage. In addition, JAK3 signaling seems
to be involved in leptin-induced NO production, p38, and
Erk1/2 MAPK pathways in leptin-induced PGE2 production,
and PKC pathway in leptin-induced NO, IL-6, and IL-8
production. Inhibition of NO production reduced the eﬀects
of leptin on PGE2, IL-6, and IL-8 production pointing to
a mediator role of NO in these leptin-induced changes in
cartilage metabolism and to a possible beneficial eﬀect of
iNOS inhibitors on OA cartilage. These findings support the
idea of leptin as a factor in the pathogenesis of osteoarthritis,
and as a possible link between obesity and osteoarthritis.
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